OncoMatch/Lung Cancer — Non-Small Cell (NSCLC)/PD-L1 (CD274)
Lung Cancer — Non-Small Cell (NSCLC)PD-L1 (CD274) Clinical Trials
PD-L1 expression, measured by IHC as tumor proportion score (TPS) or combined positive score (CPS), is the primary biomarker guiding checkpoint immunotherapy selection in NSCLC. Pembrolizumab monotherapy is first-line standard for PD-L1 TPS ≥50%; combination with chemotherapy is used at lower expression levels. Trials investigate novel checkpoint combinations, IO for driver-mutant subgroups, and predictive biomarker refinement beyond PD-L1 TPS.
Top recruiting PD-L1 (CD274) Lung Cancer — Non-Small Cell (NSCLC) trials
Ranked by phase and US site count. See all 106 trials matched to your profile →
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
National Cancer Institute (NCI)
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
National Cancer Institute (NCI)
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Eli Lilly and Company
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Summit Therapeutics
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
Summit Therapeutics
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
AstraZeneca